TEVA
Teva Pharma Ind Shs Sponsored American Deposit Receipt Repr 1 Sh
Healthcare
12/19/2013
Presented
| Date | 12/12/2013 |
| Price | $39.51 |
| Market Cap | $33.40B |
| Ent Value | $44.91B |
| P/E Ratio | 15.89x |
| Book Value | $27.37 |
| Div Yield | 2.4% |
| Shares O/S | 845.00M |
| Ave Daily Vol | 6,160,000 |
| Short Int | 1.69% |
Current
| Price | $18.15 |
| Market Cap | $20.56B |
| Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. It offers generic pharmaceutical products; and basic chemicals, as well as specialized product families, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances. The company’s pharmaceutical products comprise Copaxone for multiple sclerosis; Provigil and Nuvigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Azilect for treating Parkinson’s disease; Fentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; Amrix for muscle spasm in acute, painful, and musculoskeletal conditions; ProAir for the treatment of bronchial spasms; Qvar for long-term control of chronic bronchial asthma; and Qnasl Nasal Aerosol for seasonal nasal and year-round nasal allergy symptoms. The company also offers Treanda to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma; Tevagrastim/Ratiograstim that stimulate the production of white blood cells; Eporatio, which stimulates the production of red blood cells; Synribo for chronic myeloid leukemia; Plan B One-Step for emergency oral contraception; ParaGard, a non hormonal intrauterine contraceptive; hormone therapies for menopause/perimenopause; Enjuvia for vasomotor symptoms associated with menopause; and therapies for infertility and urinary incontinence. In addition, it produces active pharmaceutical ingredients in the areas of respiratory, cardiovascular, anti-cholesterol, central nervous system, dermatological, hormones, anti-inflammatory, oncology, immunosuppressants, and muscle relaxants. Further, the company distributes third party products. It has collaborative agreements with Lonza Group Ltd. and OncoGenex Pharmaceuticals, Inc.; and alliance agreement with Cancer Research Technology Ltd. The company was founded in 1901 and is headquartered in Petach Tikva, Israel. |
Highlights
Teva is a classic example of a company that has been mismanaged for years, said the presenter. The company has an Israeli board, which adds an additional layer of complexity to the analysis; however, the global pharmaceutical industry is evolving and he is long shares and thinks the risk/ reward is attractive under $40 as he sees the potential for substantial improvements in the company’s cost structure and overall market opportunity. In addition, fears about multiple generic competitors for Copaxone may be contributing to estimates that appear to be overly conservative for 2014 and 2015, and he sees incremental upside to estimates.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.